RBA Expected to Raise Interest Rates by 25 Basis Points in February, ANZ Forecast Says 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Dollar Slumps to Four-Year Lows as Trump Shrugs Off Weakness, Fueling Confidence Crisis 
MAS Holds Monetary Policy Steady as Strong Growth Raises Inflation Risks 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
Oil Prices Climb as U.S. Cold Snap, Dollar Weakness Tighten Supply Outlook 
Oil Prices Hit Four-Month High as Geopolitical Risks and Supply Disruptions Intensify 
U.S. and Taiwan Strengthen AI, Semiconductor, and Drone Cooperation at High-Level Economic Talks 
UK Vehicle Production Falls Sharply in 2025 Amid Cyberattack, Tariffs, and Industry Restructuring 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Philippine Economy Slows in Late 2025, Raising Expectations of Further Rate Cuts 
China to Boost Brazilian Soybean Imports in Early 2026 Amid Price Advantage 
Eli Lilly gets a subpoena from the U.S. Department of Justice with regards to its manufacturing factory in New Jersey that produces COVID-19 treatment called bamlanivimab. Based on the report, the DOJ wants the pharmaceutical company to forward some documents.
As per Reuters, while it was not specified what documents are being requested by the officials, they are something related to Eli Lilly’s factory site in Branchburg, New Jersey. The company said that it is actively participating and fully cooperating with the investigation.
The issue with Eli Lilly’s NJ plant
Earlier this month, some of Eli Lilly’s employees alleged that an executive in the NJ plant altered the documents so it can pass quality control without a problem. The papers are required by regulators for the operation of the company’s factory, but with the modification, the employees feared it would cause serious quality control issues.
It was relayed that in November 2019, inspectors from the U.S. Food and Drug Administration were sent over to check Eli Lilly’s Branchburg factory. They discovered that much of the data related to manufacturing processes were deleted while others were not inappropriately audited.
The pharmaceutical company is also said to be facing issues with its quality control and production at its plant in Indianapolis. This is the site where bamlanivimab and other medicines are being bottled.
Lilly conducting its own internal probe
As per Financial Post, Eli Lilly also launched its own investigation concerning the allegations. The company also hired counsel who will carry out an independent probe in its New Jersey facility.
“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the firm stated.
In any case, while the investigation is ongoing, Eli Lilly published the subpoena issued to them by the DOJ. This move shows that the company is being transparent with the investigation and doing its best to resolve the problems too. Meanwhile, the company could not comment further on the case as of this time since a conclusion has not been reached yet.
